Medtech M&A: Mid-Tiers Poised To Strike In 2015
This article was originally published in The Gray Sheet
Executive Summary
This may be the year that mid-sized medtech companies step up their acquisition pace to better compete against larger rivals. To be sure, these players won’t rival Medtronic, Covidien, or the other pre-megamerger partners in size or scope, but they could be in a great position to scoop up smaller companies and technologies in a bid to widen or extend their own pipelines.
You may also be interested in...
People Briefs: Medtronic, Hologic, Cook Group, AxoGen, Rivanna
Medtronic exec VP and president, restorative therapies group; Hologic announces board changes; Cook Group names new president; AxoGen chief marketing officer resigns; Rivanna Medical appoints clinical advisor.
Medtech In 2014: M&A, IPOs Bounce Back As Industry Glimpses Future Business Models
Medtech manufacturers saw 2014 as the year of the medtech mega-merger and a rebound in IPOs. But the market is changing, and companies are increasingly cast as service providers who must deliver value.
Total Ankle Replacement Sparks New Race
Orthopedic companies now target the so-called extremities as an area of capable of producing double-digit growth in sales. To be sure, the markets are considerably smaller than hips or knees, but multinational leaders can’t ignore untapped potential when their core markets are stagnant, and a new front is forming in the battle for foot and ankle supremacy around an old but still underutilized device – total ankle replacement implants.